NY-ESO-1 peptide vaccine

Known as: ESO-1 Peptide Vaccine, NY-ESO-1 peptide 
A cancer vaccine consisting of an immunogenic peptide derived from the cancer-testis antigen (NY-ESO-1), an antigen found in normal testis and… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Immune-based therapies for cancer are generating substantial interest because of the success of immune checkpoint inhibitors… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2011
Highly Cited
2011
PURPOSE Adoptive immunotherapy using tumor-infiltrating lymphocytes represents an effective cancer treatment for patients with… (More)
  • table 1
  • table 2
  • figure 1
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Ipilimumab, a monoclonal antibody against cytotoxic T lymphocyte antigen 4 (CTLA-4), has been shown to improve survival in… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
NY-ESO-1 is a "cancer-testis" antigen frequently expressed in epithelial ovarian cancer (EOC) and is among the most immunogenic… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Blockade of inhibitory signals mediated by cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) has been shown to enhance T cell… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2008
Highly Cited
2008
T cell-mediated immunity to microbes and to cancer can be enhanced by the activation of dendritic cells (DCs) via TLRs. In this… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
NY-ESO-1 is a cancer/testis antigen expressed in a range of human malignancies, and a number of vaccine strategies targeting NY… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
The presence of a metaphase cytogenetic abnormality (CA) is the key negative predictor of outcome in patients with multiple… (More)
  • figure 2
  • table 1
  • figure 1
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
NY-ESO-1 is a "cancer-testis" antigen expressed in many cancers. ISCOMATRIX is a saponin-based adjuvant that induces antibody and… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Cancer-testis antigen NY-ESO-1 is one of the most immunogenic tumor antigens defined to date. Spontaneous humoral and CD8+ T-cell… (More)
Is this relevant?